Madrigal Pharma News, Madrigal Pharma Quote, MDGL Quote

Madrigal Pharma (NQ:MDGL) Delayed: 213.49 +1.45 (0.68%)

Prev. Close

$212.04

Open

$205.19

52 Wk High

$18.24

52 Wk Low

$6.60

Day High

$217.14

Day Low

$197.43

P/E

N/A

EPS

$0.00

Volume

727,327

Friends, Peers and Foes (?): SMAR, ULTA, MU, Z, ZG (more...)

Apr 22, 2024 06:15 AM BofA Securities Starts Madrigal Pharmaceuticals (MDGL) at Underperform, 'pivoting to Rezdiffra commercial dynamics'
Apr 16, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apr 9, 2024 08:01 AM Madrigal Pharma (MDGL) Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Apr 9, 2024 08:00 AM Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Apr 9, 2024 08:00 AM Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Apr 3, 2024 04:05 PM Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 19, 2024 02:50 PM Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'
Mar 19, 2024 12:02 AM Madrigal Pharma (MDGL) Announces Pricing of Upsized $600 Million Public Offering
Mar 18, 2024 11:58 PM Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Mar 18, 2024 04:04 PM Madrigal Pharma (MDGL) Announces Proposed $500M Public Offering

Entities mentioned with MDGL